Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pre-clinical testing of the antibodies in laboratory studies showed STI-2020 was 50-fold more potent than STI-1499.
I listen to Jesspro.
AUPH has very bright future. Patience is the key. I believe AUPH will be my next winner. I buy and hold AUPH as I believe it will be my next winner. I always pick up the gold bags of AUPH shares whenever the price is right to me. I like cheapened gold bags.
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts and their employees do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next winner. I buy and hold AUPH as I believe it will be my next winner. I always pick up the gold bags of AUPH shares whenever the price is right to me. I like cheapened gold bags.
AUPH CEO Glickman says $4 billion market by 2022 ( bloombergtv.ca/2017-05-18/news/phase-iii-trials-underway-for-aurinia-pharmaceuticals-lupus-drug/ ). Motley Fool: "Sky's the limit - Peak U.S. Market Value = $6 billion assuming the low end of both patient population and pricing. EU patient population = 175,000 - 250,000. Aurinia looks to be significantly undervalued." - https://www.fool.com/investing/2017/03/31/aurinia-pharmaceuticals-where-to-from-here.aspx
Fidelity with 5,848,600 shares appears to be the #1 institutional owner of AUPH shares and NEA with 4,808,483 shares the #2. - http://www.nasdaq.com/symbol/auph/institutional-holdings - However, South Korea’s ILJIN is actually the #1 AUPH owner. ILJIN owns 14,205,457 shares or 17.35% of the 80,456,243 AUPH common shares. So Fidelity is actually the #2 AUPH owner. Robert Duggan with 5,766,887 shares is the #3 owner. NEA that used to be the #1 has become the #4 AUPH owner although NEA add 740,740 shares in 1Q-2017. - https://fintel.io/soh/us/auph/iljin-life-science
ILJIN knows about all the AUPH stories definitely better than humour412/MO/BR. ILJIN has Dr. Hyuek Joon Lee on AUPH's board of directors. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? ILJIN knows AUPH shares are GOLD BAGS based on the phase 2 results updated in early 2017, doesn't it? ILJIN owns 17.35% of AUPH (14,205,457 shares) now.https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=126747582
To those who hate AUPH/my posts:
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next previous winner. I buy and hold AUPH the way I bought and held my previous winner. I always picked/pick up the gold bags of previous winner/AUPH shares whenever the price was/is right to me. I like cheapened gold bags
I'm ABSOLUTELY not short. Nor am long. I'm just doing my job for income. I am employed. Please don't doubt my honesty. Everybody listened/listens to me and appreciates my biotech research on the previous winner/AUPH. Don't you?
https://seekingalpha.com/article/4099346-aurinia-strong-potential-focus-lupus-related-kidney-ailment
Hedge fund Polar Capital trusts AUPH CEO and starts to invest in Aurinia. And Motley Fool likes AUPH.
I'm ABSOLUTELY neither long nor short. I'm just doing my job for income. I am employed. Please don't doubt my honesty. Everybody listened/listens to me and appreciates my biotech research on the previous winner/AUPH. Don't you?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next previous winner. I buy and hold AUPH the way I bought and held my previous winner. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of previous winner/AUPH shares whenever the price was/is right to me. I like cheapened gold bags
I'm neither long nor short. I'm just doing my job for income. I am employed. Please don't doubt my honesty. Everybody listens to me and believes my biotech research on AUPH. Don't you?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
Lynch:"If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." - https://en.wikipedia.org/wiki/Peter_Lynch - Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts or their employees such as BR/dave/MO/Bruce/humour412 do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags. - This is posted by ariadinvestor: https://finance.yahoo.com/quote/AUPH/community?p=AUPH
AUPH CEO Glickman says $4 billion market by 2022 ( bloombergtv.ca/2017-05-18/news/phase-iii-trials-underway-for-aurinia-pharmaceuticals-lupus-drug/ ). Motley Fool: "Sky's the limit - Peak U.S. Market Value = $6 billion assuming the low end of both patient population and pricing. EU patient population = 175,000 - 250,000. Aurinia looks to be significantly undervalued." - https://www.fool.com/investing/2017/03/31/aurinia-pharmaceuticals-where-to-from-here.aspx
I'm doing my job for my income. I'm ABSOLUTELY not long. Nor am I short. But I am employed. Please don't doubt my honesty. Everybody listens to me and believe my biotech research on AUPH. Don't you?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
Lunacy:"Hard to find a better risk/reward play than AUPH." - Lunacy knows about AUPH better than me & my friend vidpok45. Lunacy knows about AUPH better than anybody else on any AUPH discussion forums. Lunacy believes the phase 3 results will be even better than the phase 2's because the design of phase 3 is identical to phase 2's and healthier patients will be selected for phase 3. - Peter Lynch: "If you own good companies, you'll do well." AUPH's revenue is conservatively estimated by the CEO to be $4B by 2022. Isn't it a good stock?
There are a lot of weak hands and traders out there that give up their shares way too easily. I'm holding every single one of mine for the long haul. I'm really looking forward to the developments and catalysts they're working on outside of LN to drive Value while Ph3 plays out. Hard to find a better risk/reward play than AUPH.
I'm ABSOLUTELY not long. Nor am I short. But I am employed. I'm doing my job for my income. Please don't doubt my honesty. Everybody listens to me and believe my biotech research on AUPH. Don't you?
I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags.
I like your intuitions on
picking a good investment, AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
Promising Phase 2b results presented in 2016 and updated in early 2017 continue to DERISK Voclosporin development. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for Voclosporin in the US and a 75% probability of success. We rate AUPH Outperform. https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
We rate AUPH Outperform. AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies. We project a ~$1.35BN gross market opportunity for voclosporin in the US and a 75% probability of success. Promising Phase 2b results presented in 2016 and updated in early 2017 continue to derisk Voclosporin development. https://www.docdroid.net/CIKaxJ9/aurinia-pharmaceuticals-inc-leerink1.pdf
I'm ABSOLUTELY NOT short. I'm not long, either. But I am employed. I'm doing my job for my income. Please don't doubt my honesity. Everybody listens to me and believe what I say about AUPH. Don't you?
"I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags."
- Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
I like your intuitions on
picking a good investment, AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
AUPH CEO Glickman says $4 billion market by 2022 ( bloombergtv.ca/2017-05-18/news/phase-iii-trials-underway-for-aurinia-pharmaceuticals-lupus-drug/ ). Motley Fool: "Sky's the limit - Peak U.S. Market Value = $6 billion assuming the low end of both patient population and pricing. EU patient population = 175,000 - 250,000. Aurinia looks to be significantly undervalued." - https://www.fool.com/investing/2017/03/31/aurinia-pharmaceuticals-where-to-from-here.aspx
Stellar management team, great science, Aspreva success, stellar VOC P2 results, expertise in trial design, FDA Fast Track status, etc. I simply believe that when you add it all up, it significantly boosts their odds of success in P3.
ILJIN's Hyuek Joon Lee is on AUPH's board of directors. ILJIN knows about any of the Voclosporin stories definitely better than BR, humour412, socialidiocies and Flyingtrader. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20+% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? AUPH is good, isn't it? LJIN owns 17.35% of AUPH (14,205,457 shares) now after it added 5,185,185 shares at $6.75 in March. I don't think Katrina's confidence on AUPH would be shaken by BR and humour412."
https://relationshipscience.com/hyuek-joon-lee-p157816980
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
Vid:"Duggan would be to Aurinia what Denner was to Ariad. Max value if he gets on the board."
Araidinvestor posted 3 months ago: ""Will Robert Duggan to Aurinia be Alex Denner to Ariad? I hope so. Robert Duggan Takes a 7.2% Stake in Aurinia (5,766,887 shares @6.50-8.85, AVG price 7.50?). This is great AUPH news to me."
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
AUPH: Now that Ph3 for LN is underway (AURORA Trial), where do we go from here...
Aurora Trial update:
-Phase 3 has commenced and off to a strong start having 26 trial sites already enrolling patients, and expected to have upwards of 200 sites total for a full enrollment of around 320 patients.
-This is a fully blinded study, with no interim data. Enrollment is expected to take 12-18 months, and top-line data is expected following the 52wk period of the last patient enrolled.
Any other catalysts in the meantime?
-CEO Dr. Glickman has informed everyone that they plan to announce this fall their plans of seeking additional indications for VoC.
-VoC has been studied in over 2600 patients for various conditions and indications. VoC has performed very well in a few of those trials. For various reasons when AUPH was formed they decided LN was the best opportunity for their first approval.
-Glickman confirmed they will be seeking multiple additional indications, with Dre Eye Sydrome (DES) being one of them. Out of the conditions they've already studied I would anticipate either Transplant or Psoriasis will be another indication they will pursue.
-AUPH has already been approved for a Ph3 transplant study with SPA (Special Protocol Assessment).
-VoC is a more efficient & less toxic Cyclosporine, so anything Cyclosporine has been used for is potentially a target.
-There is always the possibility that they have other autoimmune diseases in mind that they haven't already pursued in the past.
The future is bright, but can AUPH handle all that?:
-Auph has $200m on hand to get them to approval for LN. These other indications will cost a lot and additional funding will be needed. I believe it's very likely we see a partnership in the near future.
-Auph is in a great position for negotiating a partnership, so I expect the terms to be very favorable. If they announce a partnership at the same time as the new indications (which I hope they do), skies the limit!
-Auph has the attention of many types of players (tutes, longs, shorts, traders, options, etc.) so guessing the day-to-day & week-to-week action doesn’t interest me much. I've been long for well over a year and will hold for the endgame while not paying too much attention to the rollercoaster ride along the way.
VoC's History:
-Voclosporin Development History
Voclosporin has been tested in more than 2,600 patients, including studies where it was compared to placebo or active control. The safety
and tolerability profile of the drug therefore is well characterized. Phase 2 or later clinical studies that have been completed include studies
in the following indications:
Psoriasis: To date, two Phase 3 clinical studies in patients with moderate to severe psoriasis have been completed. The primary efficacy
endpoint in both studies was a reduction in Psoriasis Area and Severity Index, which is a common measure of psoriasis disease severity.
The first study treatment with voclosporin resulted in statistically significantly greater success rates than treatment with placebo by the
twelfth week. In a second study comparing voclosporin against cyclosporine, the drug was not shown to be statistically non-inferior to
cyclosporine in terms of efficacy; however, voclosporin proved superior in terms of limiting elevations in hyperlipidemia. Due to the
evolving psoriasis market dynamics and the changing standard of care for the treatment of this disease the Company has decided not to
pursue further Phase 3 development.
Renal Transplantation: A Phase 2b clinical trial in de novo renal transplant recipients was completed. Study ISA05-01, the PROMISE
Study was a six month study with a six month extension comparing voclosporin directly against tacrolimus on a background of MMF and
corticosteroids. Voclosporin was shown to be equivalent in efficacy, but superior to tacrolimus with respect to the incidence of new onset
diabetes after transplantation. In 2010, tacrolimus lost its exclusivity in most world markets and as a result, the competitive pricing
environment for voclosporin for this indication has come into question. Additionally, the more expensive development timelines for this
indication has made it a less attractive business proposition as compared to the LN indication, even when considering the fact that a special protocol assessment has been agreed to by the FDA for this indication.
Uveitis: Multiple studies in various forms of non-infectious uveitis have been completed over the past several years by Lux, a former
licensee of the Company, indicating mixed efficacy. In all but one of the studies, completed by the licensee, an impact on disease activity
was shown in the voclosporin group. However achievement of the primary end-points in multiple studies could not be shown. Uveitis is a
notoriously difficult disease to study due to the heterogeneity of the patient population and the lack of validated clinical end-points.
However in all of the uveitis studies completed, the safety results were consistent and the drug was well tolerated. The Company has now
successfully terminated its licensing agreement with Lux. In conjunction with this termination the Company has retained a portfolio of
additional patents that Lux had been prosecuting that are focused on delivering effective concentrations of voclosporin to various ocular
tissues. The Company will continue to evaluate these patents and make strategic recommendations on how they fit into the ongoing
strategic directives of the Company.
Good luck to all, and please remember this is my opinion only
A double-blinded trial is used after initial trials show particular promise. Voclosporin's phase 2 trial has shown particular promise (amazingly good results). That's why its phase 3 trial is double-blinded. Aurinia has very bright future. Patience is the key to the big success of an AUPH true long's investment. A few true longs such as Jesspro, vidpok45, zzaatt, ariadinvestor and TC might own more ARIA shares than me. We had patience and they made millions on ARIA. We will make more on AUPH.
A double-blinded study is used after initial studies show particular promise. Source: MedicineNet.com
http://www.medicinenet.com/script/main/art.asp?articlekey=11177
AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies ...
AUPH CEO Glickman says $4 billion market by 2022 ( http://bloombergtv.ca/2017-05-18/news/phase-iii-trials-underway-for-aurinia-pharmaceuticals-lupus-drug/ ). Motley Fool: "Sky's the limit - Peak U.S. Market Value = $6 billion assuming the low end of both patient population and pricing. EU patient population = 175,000 - 250,000. Aurinia looks to be significantly undervalued." - https://www.fool.com/investing/2017/03/31/aurinia-pharmaceuticals-where-to-from-here.aspx
This was posted by AI:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Advertise Here
I like your intuitions on
picking a good investment, AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
Vidpok: "Duggan would be to Aurinia what Denner was to Ariad. Max value if he gets on the board."
Araidinvestor posted 3 months ago: ""Will Robert Duggan to Aurinia be Alex Denner to Ariad? I hope so. Robert Duggan Takes a 7.2% Stake in Aurinia (5,766,887 shares @6.50-8.85, AVG price 7.50?). This is great AUPH news to me."
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
A double-blinded trial is used after initial trials show particular promise. Voclosporin's phase 2 trial has shown particular promise (amazingly good results). That's why its phase 3 trial is double-blinded. Aurinia has very bright future. Patience is the key to the big success of an AUPH true long's investment. A few true longs such as Jesspro, vidpok45, zzaatt, ariadinvestor and TC might own more ARIA shares than me. We had patience and they made millions on ARIA. We will make more on AUPH.
A double-blinded study is used after initial studies show particular promise. Source: MedicineNet.com
http://www.medicinenet.com/script/main/art.asp?articlekey=11177
AUPH is run by a management team with deep experience in lupus nephritis (LN) and corporate development, having executed the ALMS study for CellCept and selling Aspreva and ZymoGenetics to large pharma companies ...
"ILJIN's Hyuek Joon Lee is on AUPH's board of directors. ILJIN knows about any of the Voclosporin stories definitely better than BR, humour412, socialidiocies and Flyingtrader. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20+% or 5,185,185 shares of the 25,645,000 shares offered publicly on 03-13-2017? AUPH is good, isn't it? LJIN owns 17.35% of AUPH (14,205,457 shares) now after it added 5,185,185 shares at $6.75 in March. I don't think Katrina's confidence on AUPH would be shaken by BR and humour412."
https://relationshipscience.com/hyuek-joon-lee-p157816980
Dr. Hyuek Joon Lee is the Director of New Business Development for ILJIN Group and is responsible for mergers and acquisitions, and managing overseas investments, joint ventures and subsidiaries. As of October 2014 he joined the board of directors of Life Science Enterprises in Massachusetts, ..." Link: http://insiders.morningstar.com/trading/executive-profile.action?t=0P0000BLCT&PersonId=PS0000A8VP&flag=Director&insider=Hyuek_Lee&culture=en-CA&productcode=CAN&ops=clear&cur=
This is Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Stellar management team, great science, Aspreva success, stellar VOC P2 results, expertise in trial design, FDA Fast Track status, etc. I simply believe that when you add it all up, it significantly boosts their odds of success in P3.
"I don't set stop loss. I don't buy on margin. I don't sell. I add more when it pulls back. What can the manipulators/shorts do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags."
- Posted by ariadinvestor:
https://finance.yahoo.com/quote/AUPH/community?p=AUPH
Hard to find a better risk/reward play than AUPH.
LJIN KNOWS ABOUT AUPH and ALL THE Voc STORIES DEFINATELY BETTER THAN the munipulators/short hedge funds' employees. ILJIN has Dr. Hyuek Joon Lee on AUPH's board of directors. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20% or 5,185,185 shares of the 25,645,000 shares offered at $6.7 publicly on 03-13-2017? ILJIN knows AUPH shares are GOLD BAGS based on Voc 's phase 2 results updated in early 2017, doesn't it? ILJIN owns 17.35% of AUPH (14,205,457 shares) now.
LJIN KNOWS ABOUT AUPH and ALL THE Voc STORIES DEFINATELY BETTER THAN the munipulators/short hedge funds' employees. ILJIN has Dr. Hyuek Joon Lee on AUPH's board of directors. ILJIN has been being the absolutely #1 AUPH owner/investor since 2011. Why did ILJIN still acquire 20% or 5,185,185 shares of the 25,645,000 shares offered at $6.7 publicly on 03-13-2017? ILJIN knows AUPH shares are GOLD BAGS based on Voc 's phase 2 results updated in early 2017, doesn't it? ILJIN owns 17.35% of AUPH (14,205,457 shares) now.
Hard to find a better risk/reward play than AUPH.
Peter Lynch: "If you like a stock at $14 and it goes to $8, that's good if you understand the company. Take advantage of these declines. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that. Know what you own and know why you own it." Isn't Aurinia a good company given it has many +'s & its revenue is conservatively estimated to be $4B by 2022? - https://en.wikipedia.org/wiki/Peter_Lynch
I don't sell. I add more when it pulls back. I don't buy on margin. I don't set stop loss. What can the manipulators/shorts or their employees do to my AUPH shares and my money? Ah? AUPH has very bright future. Patience is the key. I believe AUPH will be my next ARIA. I buy and hold AUPH the way I bought and held ARIA. I'm planning to add more AUPH shares now that the Glickman-Cramer interview has offered a new opportunity. I always picked/pick up the gold bags of ARIA/AUPH shares whenever the price was/is right to me. I like cheapened gold bags. - https://finance.yahoo.com/quote/AUPH/community?ltr=1
MedicineNet:"Double-blinded studies are used when initial studies shows particular promise." - http://www.medicinenet.com/script/main/art.asp?articlekey=11177
Voclosporin's phase 2 trial has shown particular promise (amazingly good results). That's why its phase 3 trial is double-blinded. Aurinia has very bright future. Patience is the key to the big success of an AUPH true long's investment. A few true longs such as Jesspro, vidpok45, zzaatt, ariadinvestor and TC might own more ARIA shares than me. We had patience and they made millions on ARIA. We will make more on AUPH.
The FDA likes double blind with no peeking along the way. Shows confidence to them. Just needs to perform now and pull through the quality P3 trial. They will in my opinion. - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133975110